A National Institutes of Health advisory panel on Tuesday approved the first human use of the gene-editing technology CRISPR, for a study designed to target three types of cancer and funded by tech billionaire Sean Parker's new cancer institute.
The experiment, proposed by researchers at the University of Pennsylvania, would use CRISPR-Cas9 technology to modify patients' own T cells to make them more effective in attacking melanoma, multiple myeloma and sarcoma.
Read Full Article »